Efficient retrovirus-mediated transfer of cell-cycle control genes to transformed cells.
The use of gene therapy continues to be a promising, yet elusive, alternative for the treatment of cancer. The origins of cancer must be well understood so that the therapeutic gene can be chosen with the highest chance of successful tumor regression. The gene delivery system must be tailored for optimum transfer of the therapeutic gene to the target tissue. In order to accomplish this, we study models of G1 cell-cycle control in both normal and transformed cells in order to understand the reasons for uncontrolled cellular proliferation. We then use this information to choose the gene to be delivered to the cells. We have chosen to study p16, p21, p53 and pRb gene transfer using the pCL-retrovirus. Described here are some general concepts and specific results of our work that indicate continued hope for the development of genetically based cancer treatments.
Strauss
B E
BE
Departamento de Histologia e Embriologia, Universidade de São Paulo, Brasil. bstrauss@usp.br
Costanzi-Strauss
E
E
D000818:Animals; D002453:Cell Cycle / Q000235:genetics / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D018014:Gene Transfer Techniques; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics*; D005909:Glioblastoma / Q000235:genetics* / Q000628:therapy*; D006801:Humans; D051379:Mice; D051381:Rats; D012190:Retroviridae / Q000235:genetics*